Latest from Rush

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Melody A. Cobleigh, MD, professor of medical oncology at Rush University Medical Center, discusses antibody–drug conjugates (ADCs) under development in HER2-positive breast cancer.

Although it has been difficult to identify a specific target for triple-negative breast cancer, several therapeutic classes are showing great promise.

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

Ruta D. Rao, MD, an associate professor at Rush University Medical Center, discusses therapy de-escalation for patients with early-stage hormone receptor (HR)-positive, HER2-negative breast cancer.

Mary Jo Fidler, MD, discusses the latest developments in the treatment of patients with ALK-positive lung cancer.

Harry P. Erba, MD, PhD, and Ruben A. Mesa, MD, FACP, provide an overview of myeloproliferative neoplasms and discuss how diseases within this category may share clinical similarities.